These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29255745)

  • 21. The diagnostic value of novel ultrasound attenuation analysis in detecting liver steatosis identified by the controlled attenuation parameter: a diagnostic accuracy study.
    Jiang M; Zhang X; Wu X; Xu Z; Pan J; He H; Luo Y; Chen J
    Ann Transl Med; 2023 Jan; 11(2):38. PubMed ID: 36819532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery.
    Tavaglione F; De Vincentis A; Bruni V; Gallo IF; Carotti S; Tuccinardi D; Spagnolo G; Ciociola E; Mancina RM; Jamialahmadi O; D'Alessio R; Bottazzi B; Manfrini S; Picardi A; Perrone G; Pozzilli P; Caricato M; Vespasiani-Gentilucci U; Romeo S
    Liver Int; 2022 Feb; 42(2):374-383. PubMed ID: 34890093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease.
    Shalimar ; Kumar R; Rout G; Kumar R; Yadav R; Das P; Aggarwal S; Gunjan D; Saraya A; Nayak B
    Indian J Gastroenterol; 2020 Feb; 39(1):32-41. PubMed ID: 32185692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases.
    Masaki K; Takaki S; Hyogo H; Kobayashi T; Fukuhara T; Naeshiro N; Honda Y; Nakahara T; Ohno A; Miyaki D; Murakami E; Nagaoki Y; Kawaoka T; Tsuge M; Hiraga N; Hiramatsu A; Imamura M; Kawakami Y; Aikata H; Ochi H; Takahashi S; Arihiro K; Chayama K
    Hepatol Res; 2013 Nov; 43(11):1182-9. PubMed ID: 23551911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
    de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
    J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease.
    Shrestha R; Kc S; Thapa P; Pokharel A; Karki N; Jaishi B
    Cureus; 2021 Jul; 13(7):e16414. PubMed ID: 34422459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy.
    Karlas T; Petroff D; Garnov N; Böhm S; Tenckhoff H; Wittekind C; Wiese M; Schiefke I; Linder N; Schaudinn A; Busse H; Kahn T; Mössner J; Berg T; Tröltzsch M; Keim V; Wiegand J
    PLoS One; 2014; 9(3):e91987. PubMed ID: 24637477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.
    Thiele M; Rausch V; Fluhr G; Kjærgaard M; Piecha F; Mueller J; Straub BK; Lupșor-Platon M; De-Ledinghen V; Seitz HK; Detlefsen S; Madsen B; Krag A; Mueller S
    J Hepatol; 2018 May; 68(5):1025-1032. PubMed ID: 29343427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases.
    Ni XX; Lian M; Wu HM; Li XY; Sheng L; Bao H; Miao Q; Xiao X; Guo CJ; Li H; Ma X; Hua J
    World J Gastroenterol; 2021 Jan; 27(1):80-91. PubMed ID: 33505152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter.
    Trifan A; Stratina E; Nastasa R; Rotaru A; Stafie R; Zenovia S; Huiban L; Sfarti C; Cojocariu C; Cuciureanu T; Muzica C; Chiriac S; Girleanu I; Singeap AM; Stanciu C
    Diagnostics (Basel); 2022 Jul; 12(7):. PubMed ID: 35885657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors affecting the accuracy of controlled attenuation parameter (CAP) in assessing hepatic steatosis in patients with chronic liver disease.
    Jung KS; Kim BK; Kim SU; Chon YE; Chun KH; Kim SB; Lee SH; Ahn SS; Park JY; Kim DY; Ahn SH; Park YN; Han KH
    PLoS One; 2014; 9(6):e98689. PubMed ID: 24901649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accuracy of controlled attenuation parameter compared with ultrasound for detecting hepatic steatosis in children with severe obesity.
    Runge JH; van Giessen J; Draijer LG; Deurloo EE; Smets AMJB; Benninga MA; Koot BGP; Stoker J
    Eur Radiol; 2021 Mar; 31(3):1588-1596. PubMed ID: 32910234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
    Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
    Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B.
    Wang CY; Lu W; Hu DS; Wang GD; Cheng XJ
    World J Gastroenterol; 2014 Aug; 20(30):10585-90. PubMed ID: 25132779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.
    Chan WK; Nik Mustapha NR; Wong GL; Wong VW; Mahadeva S
    United European Gastroenterol J; 2017 Feb; 5(1):76-85. PubMed ID: 28405325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the Hepatorenal B-Mode Ratio and the "Controlled Attenuation Parameter" for the Detection and Grading of Steatosis.
    Moret A; Boursier J; Houssel Debry P; Riou J; Crouan A; Dubois M; Michalak Provost S; Aubé C; Paisant A
    Ultraschall Med; 2022 Oct; 43(5):479-487. PubMed ID: 32992377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Accuracy of Ultrasound Controlled Attenuation Parameter in Diagnosing Hepatic Fat Content.
    Atzori S; Pasha Y; Maurice JB; Taylor-Robinson SD; Campbell L; Lim AKP
    Hepat Med; 2023; 15():51-61. PubMed ID: 37325088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B.
    Cardoso AC; Beaugrand M; de Ledinghen V; Douvin C; Poupon R; Trinchet JC; Ziol M; Bedossa P; Marcellin P
    Ann Hepatol; 2015; 14(6):826-36. PubMed ID: 26436354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy.
    Shi KQ; Tang JZ; Zhu XL; Ying L; Li DW; Gao J; Fang YX; Li GL; Song YJ; Deng ZJ; Wu JM; Tang KF
    J Gastroenterol Hepatol; 2014 Jun; 29(6):1149-58. PubMed ID: 24476011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.